deferoxamine has been researched along with Hypoparathyroidism in 5 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Hypoparathyroidism: A condition caused by a deficiency of PARATHYROID HORMONE (or PTH). It is characterized by HYPOCALCEMIA and hyperphosphatemia. Hypocalcemia leads to TETANY. The acquired form is due to removal or injuries to the PARATHYROID GLANDS. The congenital form is due to mutations of genes, such as TBX1; (see DIGEORGE SYNDROME); CASR encoding CALCIUM-SENSING RECEPTOR; or PTH encoding parathyroid hormone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Delayed puberty was present in 18." | 2.72 | Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. ( De Sanctis, V; Fortini, M; Galati, MC; Gasser, T; Raiola, G; Roos, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belhoul, KM | 1 |
| Bakir, ML | 1 |
| Saned, MS | 1 |
| Kadhim, AM | 1 |
| Musallam, KM | 1 |
| Taher, AT | 1 |
| De Sanctis, V | 2 |
| Roos, M | 1 |
| Gasser, T | 1 |
| Fortini, M | 1 |
| Raiola, G | 1 |
| Galati, MC | 1 |
| Aloia, JF | 1 |
| Ostuni, JA | 1 |
| Yeh, JK | 1 |
| Zaino, EC | 1 |
| Gabutti, V | 1 |
| Piga, A | 1 |
| Sacchetti, L | 1 |
| Sandri, A | 1 |
| Biginelli, M | 1 |
| Saracco, P | 1 |
| Ferri, M | 1 |
| Vullo, C | 1 |
| Katz, M | 1 |
| Wonke, B | 1 |
| Hoffbrand, VA | 1 |
| Di Palma, A | 1 |
| Bagni, B | 1 |
1 trial available for deferoxamine and Hypoparathyroidism
| Article | Year |
|---|---|
Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia.
Topics: Adolescent; Adult; beta-Thalassemia; Body Height; Child; Child, Preschool; Deferoxamine; Female; Glu | 2006 |
4 other studies available for deferoxamine and Hypoparathyroidism
| Article | Year |
|---|---|
Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Child; Cross-Sectional Studies; Deferoxamine | 2012 |
Combined vitamin D parathyroid defect in thalassemia major.
Topics: 25-Hydroxyvitamin D 2; Adolescent; Adult; Child; Deferoxamine; Ergocalciferols; Female; Humans; Hypo | 1982 |
Quality of life and life expectancy in thalassemic patients with complications.
Topics: Adolescent; Adult; Blood Transfusion; Child; Deferoxamine; Diabetes Mellitus, Type 1; Heart Diseases | 1989 |
Endocrine complications in thalassaemia major.
Topics: Adolescent; Adult; Blood Transfusion; Deferoxamine; Diabetes Mellitus, Type 1; Female; Humans; Hypog | 1989 |